In a recent press release, Kura Oncology and Kyowa Kirin announced promising results for ziftomenib monotherapy at the 2025 ASCO Annual Meeting. The provided data shed light on the efficacy, safety, and therapeutic potential of ziftomenib, particularly for patients suffering from relapsed or refractory NPM1-mutated acute myeloid leukemia (R/RNPM1-m AML). While these findings are indeed […]
Tag: Regulatory Filings
Positive Ziftomenib Monotherapy Data at 2025 ASCO Meeting
“Kura Oncology and Kyowa Kirin have recently delivered an impactful presentation at the 2025 ASCO Annual Meeting, showcasing positive pivotal data on ziftomenib monotherapy. This promising treatment has shown significant potential in mitigating relapsed or refractory NPM1-mutant acute myeloid leukemia (R/R NPM1-m AML), a severe hematological malignancy. What makes these findings noteworthy is the observed […]